CAR-T CELL THERAPY: A REVOLUTIONARY TREATMENT IN CANCER
Vekariya Mansi Rameshbhai*, Shukla Maitri, Bhakhar Dharmik, Patel Dipen, Mr. Bhavin Bhimani, Mr. Ghanshyam Patel, Mr Jaymin Patel
ABSTRACT
The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer. Mainly, there are many types of cancer and with therapies for treatment to fight or slow down the carcinogenic cells. The immune cell (T- lymphocytes) plays a crucial role in fighting against the infected carcinogenic cells. Car t- cell therapy is widely used with immune cells, succeeding to fight against cancer. Chimeric antigen receptor T cells are T cells that have been genetically engineered to produce an artificial Tcell receptor for use in immunotherapy. The FDA-approved CAR T-cell therapy products are used only for patients with adult B-cell non-Hodgkin's lymphoma or childhood acute lymphoblastic leukemia who have already been through two unsuccessful standard treatments. Chimeric antigen receptors (CAR) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. CAR is potentially engineered in the patient’s immune cells in the laboratory and injected back into the patient’s body. Where, they bind to specific receptor, present on the surface of the tumour cells to fight cancer. It’s important for the specification of the manufacturing immune cells for the successful efficacy against the cancer. There could be succeeding future aspects, amidst the review on the car t-cell therapy.
[Full Text Article]